Logo

Bioeq Collaborates with Teva to Commercialize FYB201 (biosimilar- ranibizumab)

Share this
Bioeq Collaborates with Teva to Commercialize FYB201 (biosimilar- ranibizumab)

Bioeq Collaborates with Teva to Commercialize FYB201 (biosimilar- ranibizumab)

Shots:

  • Polpharma reported that its JV with Santo Holding- Bioeq has concluded a commercial partnership with Teva for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis) in the EU- Canada- Israel- and New Zealand
  • The agreement complements an existing agreement concluded with Coherus for the commercialization of the biosimilar in the US
  • FYB201 was originally licensed from Formycon and subsequently developed by Bioeq and has demonstrated efficacy in patients with nAMD is comparable to that of reference product- Lucentis

| Ref: Businesswire| Image: Seeking Alpha

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions